Found 46 clinical trials
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For females only
-
Currently Recruiting
Study Investigating PK PD Efficacy Safety and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
This is a multicenter, randomized, parallel arm, double-blind study with a total duration up to 82 weeks. Approximately 522 postmenopausal patients with osteoporosis will be randomized at the beginning of Treatment Period 1 (Baseline to Week 52) to receive 2 doses of either GP2411 or EU-authorized Prolia. At the beginning …
- 441 views
- 16 Sep, 2020
- 52 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Biosimilar Erythropoietin in Anaemia Treatment (Maintenance Phase Study)
This study is aimed to comprehensively establish the bio-similarity/bioequivalence in EPIAO and EPREX in terms of 52-week comparisons in efficacy, safety and immunogenicity. The targeted population is anaemia patients with end-stage chronic renal disease who previously received epoetin treatment and on haemodialysis.
- 96 views
- 29 Oct, 2020
- 19 locations
-
Multi-country trial
-
Phase 3 trial
-
Accepting pediatric ages
-
Accepting Seniors
-
10s of participants
-
An interventional trial
-
For males only
-
Currently Recruiting
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven in Patients With Hemophilia With Inhibitors
biosimilar eptacog alfa (activated) with Novoseven in 48 patients, adult and children (>12 years), not bleeding, with hemophilia A or B with inhibitors. Patients will be randomized to receive either a
- 18 views
- 15 Jan, 2021
- 13 locations
-
Phase 3 trial
-
Accepting pediatric ages
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven in Patients With Congenital Factor VII Deficiency
The purpose of this multicentre, randomized, double blinded, single dose, two-way cross-over study, is to compare the pharmacokinetics (PK) of biosimilar eptacog alfa (activated) with Novoseven
- 12 views
- 15 Jan, 2021
- 2 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Double-blind Study to Compare the Efficacy Safety and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients With Moderate-to-Severe Plaque Psoriasis
This is a randomized, double-blind, multicenter study to evaluate the efficacy, safety, and immunogenicity of FYB202 compared to Stelara in patients with Moderate-to-Severe Plaque Psoriasis.
- 0 views
- 26 Oct, 2020
- 2 locations
-
Multi-country trial
-
Phase 1 trial
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
A Phase 1 Study to Assess the Immunogenicity of QL0605 Compared to US Neulasta in Healthy Subjects
Pharmaceutical Co., Ltd. proposed biosimilar QL0605 compared to innovator product, US-Neulasta) in healthy, adult, human subjects.
- 0 views
- 11 Dec, 2020
- 2 locations
-
Phase 2 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For females only
-
Obstetrics/Gynecology (Women’s Health)
-
Currently Recruiting
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)
combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.
- 89 views
- 09 Sep, 2020
- 15 locations
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
10s of participants
-
An interventional trial
-
For all genders
-
Currently Recruiting
Extension Study of MYL-1701P-3001 for Safety and Efficacy
This Study (AFIL-IJZ-3002) is designed to evaluate the safety, efficacy and immunogenicity of MYL-1701P among a group of participants successfully completing MYL-1701P-3001 study.
- 0 views
- 26 Dec, 2020
- 1 location
-
Phase 1 trial
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For males only
-
Currently Recruiting
PK Bioequivalence Single-dose Safety Tolerability Study in Healthy Male Volunteers to Compare CBT124 & Avastin(EU&US)
This study aims to investigate the bioequivalence of new formulation of bevacizumab called CBT124 and safety when compared to two already marketed formulations, one approved in US and other in EU of Avastin(Registered Trademark). Adult healthy male aged 18 to 50 years (both inclusive) can participate in this trial. Participants …
- 0 views
- 08 Nov, 2020
- 1 location
-
Multi-country trial
-
Phase 3 trial
-
Accepting Seniors
-
Accepting adults
-
100s of participants
-
An interventional trial
-
For all genders
-
Ophthalmology
-
Currently Recruiting
Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis in Patients With nAMD
The objectives of the study are to demonstrate the equivalence of Xlucane to Lucentis in treatment of subjects with wet (ie, neovascular) age-related macular degeneration (wAMD).
- 249 views
- 08 Jul, 2020
- 109 locations